Comprehensive silencing of target-sharing micrornas is a mechanism for SIRT1 overexpression in cancer

RNA Biology

Volumn 11, Issue 11, 2014, Pages 1347-1354

  Kiga, Kotaro ^a   Fukuda Yuzawa, Yoko ^a   Tanabe, Masanobu ^b   Tsuji, Shoji ^c   Sasakawa, Chihiro ^d,e,f   Fukao, Taro ^a  

^a MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e NIPPON INSTITUTE FOR BIOLOGICAL SCIENCE   (Japan)

^f CHIBA UNIVERSITY   (Japan)

Author keywords

Cancer; DNA methylation; Epigenetics; MicroRNA; SIRT1

Indexed keywords

MESSENGER RNA; MICRORNA; SIRTUIN 1; 3' UNTRANSLATED REGION; ANTINEOPLASTIC AGENT; ETOPOSIDE; MIRN132 MICRORNA, HUMAN; MIRN212 MICRORNA, HUMAN; PROTEIN P53; SIRT1 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; CPG ISLAND; FEMALE; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NEOPLASM; NONHUMAN; SCREENING; 3' UNTRANSLATED REGION; ANIMAL; APOPTOSIS; DNA METHYLATION; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HELA CELL LINE; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

3' UNTRANSLATED REGIONS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; ETOPOSIDE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; MICE; MICRORNAS; NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIRTUIN 1; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84923636015     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.4161/rna.32093     Document Type: Article

References (26)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-67; PMID: 2188735; http://dx.doi.org/10.1016/0092-8674(90) 90186-I
2. Wiedemann LM, Morgan GJ. How are cancer associated genes activated or inactivated? Eur J Cancer 1992; 28:248-51; PMID:1567674; http://dx.doi.org/10.1016/ 0959-8049(92)90425-2
3. Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell 2013; 153:38-55; PMID: 23540689; http://dx.doi.org/10.1016/j.cell.2013.03.008
4. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004; 4:988-93; PMID:15573120; http://dx.doi.org/10.1038/nrc1507
5. Ballestar E, Esteller M. The impact of chromatin in human cancer: linking DNA methylation to gene silencing. Carcinogenesis 2002; 23:1103-9; PMID: 12117766; http://dx.doi.org/10.1093/carcin/23.7.1103
6. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107:137-48; PMID:11672522; http://dx.doi.org/ 10.1016/S0092-8674(01)00524-4
7. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA. hSIR2 (SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001; 107:149-59; PMID:11672523; http:// dx.doi.org/10.1016/S0092-8674(01)00527-X
8. Liu T, Liu PY, Marshall GM. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res 2009; 69:1702-5; PMID:19244112; http://dx.doi. org/10.1158/0008-5472.CAN-08-3365
9. Ford J, Jiang M, Milner J. Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res 2005; 65:10457-63; PMID: 16288037; http://dx.doi.org/10.1158/0008-5472. CAN-05-1923
10. Olmos Y, Brosens JJ, Lam EW. Interplay between SIRT proteins and tumour suppressor transcription factors in chemotherapeutic resistance of cancer. Drug Resist Updat 2011; 14:35-44; PMID:21195657; http://dx.doi.org/10.1016/j.drup.2010.12.001
11. Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A, Nagy TR. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 2007; 67:6612-8; PMID:17638871; http://dx.doi.org/10.1158/0008-5472.CAN-07-0085
12. Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG, et al. Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology 2009; 41:366-71; PMID:19404850; http://dx.doi.org/10.1080/ 00313020902884451
13. Sung JY, Kim R, Kim JE, Lee J. Balance between SIRT1 and DBC1 expression is lost in breast cancer. Cancer Sci 2010; 101:1738-44; PMID:20412117; http://dx.doi.org/10.1111/j.1349-7006.2010.01573.x
14. Feng AN, Zhang LH, Fan XS, Huang Q, Ye Q, Wu HY, Yang J. Expression of SIRT1 in gastric cardiac cancer and its clinicopathologic significance. Int J Surg Pathol 2011; 19:743-50; PMID:21865267; http://dx. doi.org/10.1177/1066896911412181
15. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466:835-40; PMID: 20703300; http://dx.doi.org/10.1038/nature09267
16. Iwasaki YW, Kiga K, Kayo H, Fukuda-Yuzawa Y, Weise J, Inada T, Tomita M, Ishihama Y, Fukao T. Global microRNA elevation by inducible Exportin 5 regulates cell cycle entry. RNA 2013; 19:490-7; PMID: 23431327; http://dx.doi.org/10.1261/rna.036608.112
17. Hino K, Tsuchiya K, Fukao T, Kiga K, Okamoto R, Kanai T, Watanabe M. Inducible expression of micro-RNA-194 is regulated by HNF-1alpha during intestinal epithelial cell differentiation. RNA 2008; 14:1433-42; PMID:18492795; http://dx.doi.org/10.1261/ rna.810208
18. Fukao T, Fukuda Y, Kiga K, Sharif J, Hino K, Enomoto Y, Kawamura A, Nakamura K, Takeuchi T, Tanabe M. An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling. Cell 2007; 129:617-31; PMID: 17482553; http://dx.doi.org/10.1016/j.cell.2007.02.048
19. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120:15-20; PMID:15652477; http://dx.doi.org/ 10.1016/j.cell.2004.12.035
20. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of micro-RNAs. Genome Res 2009; 19:92-105; PMID: 18955434; http://dx.doi.org/10.1101/gr.082701.108
21. Clark SJ, Melki J. DNA methylation and gene silencing in cancer: which is the guilty party? Oncogene 2002; 21:5380-7; PMID:12154400; http://dx.doi.org/ 10.1038/sj.onc.1205598
22. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, Labourier E, Hahn SA. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007; 26:4442-52; PMID: 17237814; http://dx.doi.org/10.1038/sj.onc.1210228
23. Kayo H, Kiga K, Fukuda-Yuzawa Y, Hedlund S, Murakami K, De La Rosa-Velazquez IA, Kimura T, Shimoda K, Tanabe M, Fukao T. miR-212 and miR-132 are dispensable for mouse mammary gland development. Nat Genet 2014; 46:802-4; PMID:25070796; http://dx. doi.org/10.1038/ng.2990
24. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, vanTuinen P, Ledbetter DH, Barker DF, Nakamura Y, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989; 244:217-21; PMID:2649981; http://dx. doi.org/10.1126/science.2649981
25. Yamakuchi M. MicroRNA Regulation of SIRT1. Front Physiol 2012; 3:68; PMID:22479251; http://dx.doi. org/10.3389/fphys.2012.00068
26. Wong KY, Yu L, Chim CS. DNA methylation of tumor suppressor miRNA genes: a lesson from themiR-34 family. Epigenomics 2011; 3:83-92; PMID:22126155; http://dx. doi.org/10.2217/epi.10.74